DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products to combat the fentanyl and substance use disorder crises, today announced financial results for the third quarter ended September 30, 2023, and provided an update on recent corporate developments.
- “The change in the company name to DMK Pharmaceuticals Corporation and the new executive team are the first steps in this process.
- The DMK research study is designed to evaluate the efficacy of ZIMHI®, intramuscular naloxone, versus the standard of care generic version of NARCAN®, intranasal naloxone.
- Revenues for the third quarter ending September 30, 2023 were $0.0 million, compared to $1.5 million for the same period in 2022.
- Research and development (R&D) expense for the third quarter of 2023 was $0.4 million compared to $2.0 million in the third quarter of 2022.